ID   STK11_HUMAN             Reviewed;         433 AA.
AC   Q15831; B2RBX7; E7EW76;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 190.
DE   RecName: Full=Serine/threonine-protein kinase STK11;
DE            EC=2.7.11.1;
DE   AltName: Full=Liver kinase B1;
DE            Short=LKB1;
DE            Short=hLKB1;
DE   AltName: Full=Renal carcinoma antigen NY-REN-19;
DE   Flags: Precursor;
GN   Name=STK11; Synonyms=LKB1, PJS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INVOLVEMENT IN PJS.
RC   TISSUE=Liver;
RX   PubMed=9425897; DOI=10.1038/ng0198-38;
RA   Jenne D.E., Reimann H., Nezu J., Friedl W., Loff S., Jeschke R.,
RA   Mueller O., Back W., Zimmer M.;
RT   "Peutz-Jeghers syndrome is caused by mutations in a novel serine
RT   threonine kinase.";
RL   Nat. Genet. 18:38-43(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9537235;
RA   Bignell G.R., Barfoot R., Seal S., Collins N., Warren W.,
RA   Stratton M.R.;
RT   "Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome
RT   gene in sporadic breast cancer.";
RL   Cancer Res. 58:1384-1386(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [8]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=11212897; DOI=10.1023/A:1006442024874;
RA   Sobottka S.B., Haase M., Fitze G., Hahn M., Schackert H.K.,
RA   Schackert G.;
RT   "Frequent loss of heterozygosity at the 19p13.3 locus without
RT   LKB1/STK11 mutations in human carcinoma metastases to the brain.";
RL   J. Neurooncol. 49:187-195(2000).
RN   [9]
RP   IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF SMAD4 AND STK11IP, AND
RP   INTERACTION WITH SMAD4 AND STK11IP.
RX   PubMed=11741830; DOI=10.1093/hmg/10.25.2869;
RA   Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M.,
RA   Ashworth A.;
RT   "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers
RT   syndrome kinase LKB1.";
RL   Hum. Mol. Genet. 10:2869-2877(2001).
RN   [10]
RP   SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, FUNCTION, MUTAGENESIS OF
RP   LYS-78 AND THR-189, AND PHOSPHORYLATION AT THR-189.
RX   PubMed=11430832; DOI=10.1016/S1097-2765(01)00258-1;
RA   Karuman P., Gozani O., Odze R.D., Zhou X.C., Zhu H., Shaw R.,
RA   Brien T.P., Bozzuto C.D., Ooi D., Cantley L.C., Yuan J.;
RT   "The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent
RT   cell death.";
RL   Mol. Cell 7:1307-1319(2001).
RN   [11]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=12097271;
RA   Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B.,
RA   Engles J.M., Westra W.H., Herman J.G., Sidransky D.;
RT   "Inactivation of LKB1/STK11 is a common event in adenocarcinomas of
RT   the lung.";
RL   Cancer Res. 62:3659-3662(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STRADA,
RP   PHOSPHORYLATION AT THR-336 AND THR-363, AND CHARACTERIZATION OF
RP   VARIANT SPORADIC CANCER TYR-176.
RX   PubMed=12805220; DOI=10.1093/emboj/cdg292;
RA   Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A.,
RA   Alessi D.R., Clevers H.C.;
RT   "Activation of the tumour suppressor kinase LKB1 by the STE20-like
RT   pseudokinase STRAD.";
RL   EMBO J. 22:3062-3072(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-194, IDENTIFICATION
RP   IN A COMPLEX WITH STRADA AND CAB39, AND INTERACTION WITH STRADA;
RP   STRADB; CAB39 AND CAB39L.
RX   PubMed=14517248; DOI=10.1093/emboj/cdg490;
RA   Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A.,
RA   Schutkowski M., Prescott A.R., Clevers H.C., Alessi D.R.;
RT   "MO25alpha/beta interact with STRADalpha/beta enhancing their ability
RT   to bind, activate and localize LKB1 in the cytoplasm.";
RL   EMBO J. 22:5102-5114(2003).
RN   [14]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=15016379; DOI=10.1016/S0092-8674(04)00114-X;
RA   Baas A.F., Kuipers J., van der Wel N.N., Batlle E., Koerten H.K.,
RA   Peters P.J., Clevers H.C.;
RT   "Complete polarization of single intestinal epithelial cells upon
RT   activation of LKB1 by STRAD.";
RL   Cell 116:457-466(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-194.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A.,
RA   Boudeau J., Hawley S.A., Udd L., Maekelae T.P., Hardie D.G.,
RA   Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK
RT   subfamily, including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [16]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=15021901; DOI=10.1038/sj.onc.1207502;
RA   Carretero J., Medina P.P., Pio R., Montuenga L.M.,
RA   Sanchez-Cespedes M.;
RT   "Novel and natural knockout lung cancer cell lines for the LKB1/STK11
RT   tumor suppressor gene.";
RL   Oncogene 23:4037-4040(2004).
RN   [17]
RP   FUNCTION.
RX   PubMed=15733851; DOI=10.1016/j.febslet.2005.01.042;
RA   Jaleel M., McBride A., Lizcano J.M., Deak M., Toth R., Morrice N.A.,
RA   Alessi D.R.;
RT   "Identification of the sucrose non-fermenting related kinase SNRK, as
RT   a novel LKB1 substrate.";
RL   FEBS Lett. 579:1417-1423(2005).
RN   [18]
RP   FUNCTION, INTERACTION WITH PTEN, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANT PJS ASN-176.
RX   PubMed=15987703; DOI=10.1093/hmg/ddi225;
RA   Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A.,
RA   Picard D., Antonarakis S.E.;
RT   "LKB1 interacts with and phosphorylates PTEN: a functional link
RT   between two proteins involved in cancer predisposing syndromes.";
RL   Hum. Mol. Genet. 14:2209-2219(2005).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TP53.
RX   PubMed=17108107; DOI=10.1158/0008-5472.CAN-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [20]
RP   INTERACTION WITH WDR6.
RX   PubMed=17216128; DOI=10.1007/s11010-006-9402-5;
RA   Xie X., Wang Z., Chen Y.;
RT   "Association of LKB1 with a WD-repeat protein WDR6 is implicated in
RT   cell growth arrest and p27(Kip1) induction.";
RL   Mol. Cell. Biochem. 301:115-122(2007).
RN   [21]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17711506; DOI=10.1111/j.1349-7006.2007.00585.x;
RA   Onozato R., Kosaka T., Achiwa H., Kuwano H., Takahashi T., Yatabe Y.,
RA   Mitsudomi T.;
RT   "LKB1 gene mutations in Japanese lung cancer patients.";
RL   Cancer Sci. 98:1747-1751(2007).
RN   [22]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17676035; DOI=10.1038/nature06030;
RA   Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P.,
RA   Torrice C., Wu M.C., Shimamura T., Perera S.A., Liang M.C., Cai D.,
RA   Naumov G.N., Bao L., Contreras C.M., Li D., Chen L., Krishnamurthy J.,
RA   Koivunen J., Chirieac L.R., Padera R.F., Bronson R.T., Lindeman N.I.,
RA   Christiani D.C., Lin X., Shapiro G.I., Janne P.A., Johnson B.E.,
RA   Meyerson M., Kwiatkowski D.J., Castrillon D.H., Bardeesy N.,
RA   Sharpless N.E., Wong K.K.;
RT   "LKB1 modulates lung cancer differentiation and metastasis.";
RL   Nature 448:807-810(2007).
RN   [23]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=17384680; DOI=10.1038/sj.onc.1210418;
RA   Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y.,
RA   Matsuno Y., Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J.;
RT   "Prevalence and specificity of LKB1 genetic alterations in lung
RT   cancers.";
RL   Oncogene 26:5911-5918(2007).
RN   [24]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=18594528; DOI=10.1038/sj.bjc.6604469;
RA   Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X.,
RA   Naoki K., Okamoto I., Nakagawa K., Yeap B.Y., Meyerson M., Wong K.K.,
RA   Richards W.G., Sugarbaker D.J., Johnson B.E., Janne P.A.;
RT   "Mutations in the LKB1 tumour suppressor are frequently detected in
RT   tumours from Caucasian but not Asian lung cancer patients.";
RL   Br. J. Cancer 99:245-252(2008).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-428, AND
RP   MUTAGENESIS OF SER-428.
RX   PubMed=18321849; DOI=10.1074/jbc.M708208200;
RA   Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.;
RT   "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation
RT   increases LKB1 nucleus export and apoptosis in endothelial cells.";
RL   J. Biol. Chem. 283:12446-12455(2008).
RN   [26]
RP   INTERACTION WITH SIRT1, ACETYLATION AT LYS-44; LYS-48; LYS-96; LYS-97;
RP   LYS-296; LYS-311; LYS-416; LYS-423 AND LYS-431, AND MUTAGENESIS OF
RP   LYS-44; LYS-48; LYS-96 AND LYS-97.
RX   PubMed=18687677; DOI=10.1074/jbc.M805711200;
RA   Lan F., Cacicedo J.M., Ruderman N., Ido Y.;
RT   "SIRT1 modulation of the acetylation status, cytosolic localization,
RT   and activity of LKB1. Possible role in AMP-activated protein kinase
RT   activation.";
RL   J. Biol. Chem. 283:27628-27635(2008).
RN   [27]
RP   ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-428, AND MUTAGENESIS OF SER-428.
RX   PubMed=18854309; DOI=10.1074/jbc.M806153200;
RA   Denison F.C., Hiscock N.J., Carling D., Woods A.;
RT   "Characterization of an alternative splice variant of LKB1.";
RL   J. Biol. Chem. 284:67-76(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [29]
RP   INVOLVEMENT IN LUNG CANCER.
RX   PubMed=20559149; DOI=10.1097/JTO.0b013e3181e05016;
RA   Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y.,
RA   Pao W., Chen H., Ji H.;
RT   "Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung
RT   adenocarcinomas.";
RL   J. Thorac. Oncol. 5:1130-1135(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [32]
RP   REVIEW ON FUNCTION.
RX   PubMed=21396365; DOI=10.1016/j.febslet.2011.03.010;
RA   Alexander A., Walker C.L.;
RT   "The role of LKB1 and AMPK in cellular responses to stress and
RT   damage.";
RL   FEBS Lett. 585:952-957(2011).
RN   [33]
RP   REVIEW ON INVOLVEMENT IN LUNG CANCER.
RX   PubMed=21380642; DOI=10.1007/s13238-011-1021-6;
RA   Gao Y., Ge G., Ji H.;
RT   "LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor
RT   suppressor.";
RL   Protein Cell 2:99-107(2011).
RN   [34]
RP   ENZYME REGULATION, INTERACTION WITH NR4A1, AND SUBCELLULAR LOCATION.
RX   PubMed=22983157; DOI=10.1038/nchembio.1069;
RA   Zhan Y.Y., Chen Y., Zhang Q., Zhuang J.J., Tian M., Chen H.Z.,
RA   Zhang L.R., Zhang H.K., He J.P., Wang W.J., Wu R., Wang Y., Shi C.,
RA   Yang K., Li A.Z., Xin Y.Z., Li T.Y., Yang J.Y., Zheng Z.H., Yu C.D.,
RA   Lin S.C., Chang C., Huang P.Q., Lin T., Wu Q.;
RT   "The orphan nuclear receptor Nur77 regulates LKB1 localization and
RT   activates AMPK.";
RL   Nat. Chem. Biol. 8:897-904(2012).
RN   [35]
RP   INTERACTION WITH NISCH, AND SUBCELLULAR LOCATION.
RX   PubMed=23572524; DOI=10.1074/jbc.M112.418103;
RA   Jain P., Baranwal S., Dong S., Struckhoff A.P., Worthylake R.A.,
RA   Alahari S.K.;
RT   "Integrin-binding protein nischarin interacts with tumor suppressor
RT   liver kinase B1 (LKB1) to regulate cell migration of breast epithelial
RT   cells.";
RL   J. Biol. Chem. 288:15495-15509(2013).
RN   [36]
RP   SUBCELLULAR LOCATION (ISOFORM 2), AND PHOSPHORYLATION (ISOFORM 2).
RX   PubMed=23612973; DOI=10.1074/jbc.M112.443580;
RA   Zhu H., Moriasi C.M., Zhang M., Zhao Y., Zou M.H.;
RT   "Phosphorylation of serine 399 in LKB1 protein short form by protein
RT   kinase Czeta is required for its nucleocytoplasmic transport and
RT   consequent AMP-activated protein kinase (AMPK) activation.";
RL   J. Biol. Chem. 288:16495-16505(2013).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31 AND SER-401, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   FUNCTION, AND INTERACTION WITH CDKN1A.
RX   PubMed=25329316; DOI=10.1371/journal.pgen.1004721;
RA   Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J.,
RA   Grueso J., Hernandez-Losa J., Moline T., Canals F., Ferrer B.,
RA   Cortes J., Bastian B., Cajal S.R.Y., Martin-Caballero J., Flores J.M.,
RA   Vivancos A., Garcia-Patos V., Recio J.A.;
RT   "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor
RT   mediating CDKN1A (p21WAF1/CIP1) degradation.";
RL   PLoS Genet. 10:E1004721-E1004721(2014).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 43-347 IN COMPLEX WITH
RP   STRADA AND CAB39, ENZYME REGULATION, CHARACTERIZATION OF VARIANTS
RP   SPORADIC CANCER MET-66; GLY-86; ARG-123; SER-157; ASP-163; PRO-170;
RP   SER-171; ARG-174; TYR-176; ASN-177; GLU-181; GLN-199; THR-205;
RP   PHE-216; VAL-223; PRO-230; PRO-232; ARG-245; PRO-250; HIS-272;
RP   TYR-277; GLN-285 AND SER-315, AND MUTAGENESIS OF ARG-74; ASP-194 AND
RP   PHE-204.
RX   PubMed=19892943; DOI=10.1126/science.1178377;
RA   Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.;
RT   "Structure of the LKB1-STRAD-MO25 complex reveals an allosteric
RT   mechanism of kinase activation.";
RL   Science 326:1707-1711(2009).
RN   [41]
RP   VARIANTS PJS 50-LEU--ASP-53 DEL; ASN-176 AND CYS-308, CHARACTERIZATION
RP   OF VARIANTS PJS PRO-67; ASN-176 AND CYS-308, AND MUTAGENESIS OF
RP   LYS-78.
RX   PubMed=9837816; DOI=10.1086/302159;
RA   Mehenni H., Gehrig C., Nezu J., Oku A., Shimane M., Rossier C.,
RA   Guex N., Blouin J.L., Scott H.S., Antonarakis S.E.;
RT   "Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence
RT   for allelic and locus heterogeneity.";
RL   Am. J. Hum. Genet. 63:1641-1650(1998).
RN   [42]
RP   VARIANT TGCT ASP-163.
RX   PubMed=9605748;
RA   Avizienyte E., Roth S., Loukola A., Hemminki A., Lothe R.A.,
RA   Stenwig A.E., Fossaa S.D., Salovaara R., Aaltonen L.A.;
RT   "Somatic mutations in LKB1 are rare in sporadic colorectal and
RT   testicular tumors.";
RL   Cancer Res. 58:2087-2090(1998).
RN   [43]
RP   VARIANTS COLORECTAL CANCER SER-171; LYS-199; ASN-208; ASP-215; LEU-354
RP   AND MET-367.
RX   PubMed=9731485;
RA   Dong S.M., Kim K.M., Kim S.Y., Shin M.S., Na E.Y., Lee S.H.,
RA   Park W.S., Yoo N.J., Jang J.J., Yoon C.Y., Kim J.W., Kim S.Y.,
RA   Yang Y.M., Kim S.H., Kim C.S., Lee J.Y.;
RT   "Frequent somatic mutations in serine/threonine kinase 11/Peutz-
RT   Jeghers syndrome gene in left-sided colon cancer.";
RL   Cancer Res. 58:3787-3790(1998).
RN   [44]
RP   VARIANT COLORECTAL CANCER HIS-314.
RX   PubMed=9809980;
RA   Resta N., Simone C., Mareni C., Montera M., Gentile M., Susca F.,
RA   Gristina R., Pozzi S., Bertario L., Bufo P., Carlomagno N.,
RA   Ingrosso M., Rossini F.P., Tenconi R., Guanti G.;
RT   "STK11 mutations in Peutz-Jeghers syndrome and sporadic colon
RT   cancer.";
RL   Cancer Res. 58:4799-4801(1998).
RN   [45]
RP   VARIANT PJS ASN-247 DEL.
RX   PubMed=9760200; DOI=10.1007/s004390050801;
RA   Nakagawa H., Koyama K., Miyoshi Y., Ando H., Baba S., Watatani M.,
RA   Yasutomi M., Matsuura N., Monden M., Nakamura Y.;
RT   "Nine novel germline mutations of STK11 in ten families with Peutz-
RT   Jeghers syndrome.";
RL   Hum. Genet. 103:168-172(1998).
RN   [46]
RP   VARIANT GASTRIC CARCINOMA LEU-324.
RX   PubMed=9683800;
RA   Park W.S., Moon Y.W., Yang Y.M., Kim Y.S., Kim Y.D., Fuller B.G.,
RA   Vortmeyer A.O., Fogt F., Lubensky I.A., Zhuang Z.;
RT   "Mutations of the STK11 gene in sporadic gastric carcinoma.";
RL   Int. J. Oncol. 13:601-604(1998).
RN   [47]
RP   VARIANTS PJS PRO-67 AND 303-ILE--GLN-306 DELINS ASN.
RX   PubMed=9428765; DOI=10.1038/34432;
RA   Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S.,
RA   Loukola A., Bignell G., Warren W., Aminoff M., Hoeglund P.,
RA   Jaervinen H., Kristo P., Pelin K., Ridanpaeae M., Salovaara R.,
RA   Toro T., Bodmer W., Olschwang S., Olsen A.S., Stratton M.R.,
RA   de la Chapelle A., Aaltonen L.A.;
RT   "A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.";
RL   Nature 391:184-187(1998).
RN   [48]
RP   VARIANT LUNG CANCER VAL-194.
RX   PubMed=10079245; DOI=10.1016/S0002-9440(10)65314-X;
RA   Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M.,
RA   Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K.,
RA   Kokkola A., Jarvinen H., Aaltonen L.A.;
RT   "LKB1 somatic mutations in sporadic cancers.";
RL   Am. J. Pathol. 154:677-681(1999).
RN   [49]
RP   VARIANTS PJS 162-ASN--MET-164; ASN-194 AND LYS-297.
RX   PubMed=10408777;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<476::AID-HUMU7>3.0.CO;2-2;
RA   Westerman A.M., Entius M.M., Boor P.P.C., Koole R., de Baar E.,
RA   Offerhaus G.J.A., Lubinski J., Lindhout D., Halley D.J.J.,
RA   de Rooij F.W.M., Wilson J.H.P.;
RT   "Novel mutations in the LKB1/STK11 gene in Dutch Peutz-Jeghers
RT   families.";
RL   Hum. Mutat. 13:476-481(1999).
RN   [50]
RP   CHARACTERIZATION OF VARIANT TGCT ASP-163.
RX   PubMed=9887330; DOI=10.1093/hmg/8.1.45;
RA   Ylikorkala A., Avizienyte E., Tomlinson I.P., Tiainen M., Roth S.,
RA   Loukola A., Hemminki A., Johansson M., Sistonen P., Markie D.,
RA   Neale K., Phillips R., Zauber P., Twama T., Sampson J., Jaervinen H.,
RA   Maekelae T.P., Aaltonen L.A.;
RT   "Mutations and impaired function of LKB1 in familial and non-familial
RT   Peutz-Jeghers syndrome and a sporadic testicular cancer.";
RL   Hum. Mol. Genet. 8:45-51(1999).
RN   [51]
RP   VARIANT OVARIAN CARCINOMA LEU-281.
RX   PubMed=10429654; DOI=10.1111/j.1349-7006.1999.tb00793.x;
RA   Nishioka Y., Kobayashi K., Sagae S., Sugimura M., Ishioka S.,
RA   Nagata M., Terasawa K., Tokino T., Kudo R.;
RT   "Mutational analysis of STK11 gene in ovarian carcinomas.";
RL   Jpn. J. Cancer Res. 90:629-632(1999).
RN   [52]
RP   VARIANTS MELANOMA ASP-49 AND ARG-135.
RX   PubMed=10201537; DOI=10.1046/j.1523-1747.1999.00551.x;
RA   Rowan A., Bataille V., MacKie R., Healy E., Bicknell D., Bodmer W.,
RA   Tomlinson I.;
RT   "Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic
RT   malignant melanomas.";
RL   J. Invest. Dermatol. 112:509-511(1999).
RN   [53]
RP   VARIANT MELANOMA TYR-194.
RX   PubMed=10208439; DOI=10.1038/sj.onc.1202486;
RA   Guldberg P., thor Straten P., Ahrenkiel V., Seremet T., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in
RT   malignant melanoma.";
RL   Oncogene 18:1777-1780(1999).
RN   [54]
RP   VARIANTS PJS CYS-239 AND SER-315.
RX   PubMed=12372054; DOI=10.1034/j.1399-0004.2002.620405.x;
RA   Scott R.J., Crooks R., Meldrum C.J., Thomas L., Smith C.J.A.,
RA   Mowat D., McPhillips M., Spigelman A.D.;
RT   "Mutation analysis of the STK11/LKB1 gene and clinical characteristics
RT   of an Australian series of Peutz-Jeghers syndrome patients.";
RL   Clin. Genet. 62:282-287(2002).
RN   [55]
RP   VARIANTS CERVICAL CANCER LYS-14; PRO-160 AND LEU-231, AND VARIANT
RP   CERVICAL CARCINOMA MET-66.
RX   PubMed=12533684;
RA   Kuragaki C., Enomoto T., Ueno Y., Sun H., Fujita M., Nakashima R.,
RA   Ueda Y., Wada H., Murata Y., Toki T., Konishi I., Fujii S.;
RT   "Mutations in the STK11 gene characterize minimal deviation
RT   adenocarcinoma of the uterine cervix.";
RL   Lab. Invest. 83:35-45(2003).
RN   [56]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-87.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [57]
RP   VARIANT PJS GLY-16.
RX   PubMed=21411391; DOI=10.1016/j.clinre.2010.11.008;
RA   Liu L., Du X., Nie J.;
RT   "A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers
RT   syndrome patient significantly diminished p53 activity.";
RL   Clin. Res. Hepatol. Gastroenterol. 35:221-226(2011).
CC   -!- FUNCTION: Tumor suppressor serine/threonine-protein kinase that
CC       controls the activity of AMP-activated protein kinase (AMPK)
CC       family members, thereby playing a role in various processes such
CC       as cell metabolism, cell polarity, apoptosis and DNA damage
CC       response. Acts by phosphorylating the T-loop of AMPK family
CC       proteins, thus promoting their activity: phosphorylates PRKAA1,
CC       PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2,
CC       SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-
CC       AMPK family proteins such as STRADA, PTEN and possibly p53/TP53.
CC       Acts as a key upstream regulator of AMPK by mediating
CC       phosphorylation and activation of AMPK catalytic subunits PRKAA1
CC       and PRKAA2 and thereby regulates processes including: inhibition
CC       of signaling pathways that promote cell growth and proliferation
CC       when energy levels are low, glucose homeostasis in liver,
CC       activation of autophagy when cells undergo nutrient deprivation,
CC       and B-cell differentiation in the germinal center in response to
CC       DNA damage. Also acts as a regulator of cellular polarity by
CC       remodeling the actin cytoskeleton. Required for cortical neuron
CC       polarization by mediating phosphorylation and activation of BRSK1
CC       and BRSK2, leading to axon initiation and specification. Involved
CC       in DNA damage response: interacts with p53/TP53 and recruited to
CC       the CDKN1A/WAF1 promoter to participate in transcription
CC       activation. Able to phosphorylate p53/TP53; the relevance of such
CC       result in vivo is however unclear and phosphorylation may be
CC       indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also
CC       acts as a mediator of p53/TP53-dependent apoptosis via interaction
CC       with p53/TP53: translocates to the mitochondrion during apoptosis
CC       and regulates p53/TP53-dependent apoptosis pathways. In vein
CC       endothelial cells, inhibits PI3K/Akt signaling activity and thus
CC       induces apoptosis in response to the oxidant peroxynitrite (in
CC       vitro). Regulates UV radiation-induced DNA damage response
CC       mediated by CDKN1A. In association with NUAK1, phosphorylates
CC       CDKN1A in response to UV radiation and contributes to its
CC       degradation which is necessary for optimal DNA repair
CC       (PubMed:25329316). {ECO:0000269|PubMed:11430832,
CC       ECO:0000269|PubMed:12805220, ECO:0000269|PubMed:14517248,
CC       ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15016379,
CC       ECO:0000269|PubMed:15733851, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:18321849,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:25329316}.
CC   -!- FUNCTION: Isoform 2: Has a role in spermiogenesis. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:14976552}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- ENZYME REGULATION: Activated by forming a complex with STRAD
CC       (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or
CC       CAB39L/MO25beta): STRADA (or STRADB)-binding promotes a
CC       conformational change of STK11/LKB1 in an active conformation,
CC       which is stabilized by CAB39/MO25alpha (or CAB39L/MO25beta)
CC       interacting with the STK11/LKB1 activation loop. Sequestration in
CC       the nucleus by NR4A1 prevents it from phosphorylating and
CC       activating cytoplasmic AMPK. {ECO:0000269|PubMed:19892943,
CC       ECO:0000269|PubMed:22983157}.
CC   -!- SUBUNIT: Catalytic component of a trimeric complex composed of
CC       STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25
CC       (CAB39/MO25alpha or CAB39L/MO25beta): the complex tethers
CC       STK11/LKB1 in the cytoplasm and stimulates its catalytic activity.
CC       Found in a ternary complex composed of SMAD4, STK11/LKB1 and
CC       STK11IP. Interacts with p53/TP53, SMAD4, STK11IP and WDR6.
CC       Interacts with NR4A1. Interacts with NISCH; this interaction may
CC       increase STK11 activity. Interacts with PTEN; leading to PTEN
CC       phosphorylation. Interacts with SIRT1; the interaction
CC       deacetylates STK11. Interacts with CDKN1A.
CC       {ECO:0000269|PubMed:11741830, ECO:0000269|PubMed:12805220,
CC       ECO:0000269|PubMed:14517248, ECO:0000269|PubMed:15987703,
CC       ECO:0000269|PubMed:17108107, ECO:0000269|PubMed:17216128,
CC       ECO:0000269|PubMed:18687677, ECO:0000269|PubMed:19892943,
CC       ECO:0000269|PubMed:22983157, ECO:0000269|PubMed:23572524,
CC       ECO:0000269|PubMed:25329316}.
CC   -!- INTERACTION:
CC       Q9Y376:CAB39; NbExp=7; IntAct=EBI-306838, EBI-306905;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-306838, EBI-295634;
CC       Q9BT78:COPS4; NbExp=2; IntAct=EBI-306838, EBI-742413;
CC       Q13451:FKBP5; NbExp=4; IntAct=EBI-306838, EBI-306914;
CC       P07900:HSP90AA1; NbExp=2; IntAct=EBI-306838, EBI-296047;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-306838, EBI-352572;
CC       Q96L34:MARK4; NbExp=2; IntAct=EBI-306838, EBI-302319;
CC       Q7RTN6:STRADA; NbExp=12; IntAct=EBI-306838, EBI-1109114;
CC       Q9C0K7:STRADB; NbExp=6; IntAct=EBI-306838, EBI-306893;
CC       Q8NFZ5:TNIP2; NbExp=5; IntAct=EBI-306838, EBI-359372;
CC       Q9NNW5:WDR6; NbExp=3; IntAct=EBI-306838, EBI-1568315;
CC       P63104:YWHAZ; NbExp=6; IntAct=EBI-306838, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Membrane {ECO:0000250}.
CC       Mitochondrion. Note=A small fraction localizes at membranes (By
CC       similarity). Relocates to the cytoplasm when bound to STRAD
CC       (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or
CC       CAB39L/MO25beta). Translocates to the mitochondrion during
CC       apoptosis. Translocates to the cytoplasm in response to metformin
CC       or peroxynitrite treatment. PTEN promotes cytoplasmic
CC       localization. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus
CC       {ECO:0000269|PubMed:23612973}. Cytoplasm
CC       {ECO:0000269|PubMed:23612973}. Note=Predominantly nuclear, but
CC       translocates to the cytoplasm in response to metformin or
CC       peroxynitrite treatment.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=LKB1(L);
CC         IsoId=Q15831-1; Sequence=Displayed;
CC       Name=2; Synonyms=LKB1(S);
CC         IsoId=Q15831-2; Sequence=VSP_041746;
CC         Note=Phosphorylated by PKC/PRKCZ on Ser-399.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Strongest expression
CC       in testis and fetal liver.
CC   -!- PTM: Phosphorylated by ATM at Thr-363 following ionizing radiation
CC       (IR). Phosphorylation at Ser-428 by RPS6KA1 and/or some PKA is
CC       required to inhibit cell growth. Phosphorylation at Ser-428 is
CC       also required during neuronal polarization to mediate
CC       phosphorylation of BRSK1 and BRSK2 (By similarity).
CC       Phosphorylation by PKC/PRKCZ at Ser-428 promotes peroxynitrite-
CC       induced nuclear export of STK11, leading to PTEN activation and
CC       subsequent inhibition of AKT signaling. Phosphorylation by
CC       PKC/PRKCZ at Ser-399 in isoform 2 promotes metformin (or
CC       peroxynitrite)-induced nuclear export of STK11 and activation of
CC       AMPK. UV radiation-induced phosphorylation at Thr-363 mediates
CC       CDKN1A degradation (By similarity). {ECO:0000250|UniProtKB:Q9WTK7,
CC       ECO:0000269|PubMed:11430832, ECO:0000269|PubMed:12805220,
CC       ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:18854309}.
CC   -!- PTM: Acetylated. Deacetylation at Lys-48 enhances cytoplasmic
CC       localization and kinase activity in vitro.
CC       {ECO:0000269|PubMed:18687677}.
CC   -!- DISEASE: Peutz-Jeghers syndrome (PJS) [MIM:175200]: An autosomal
CC       dominant disorder characterized by melanocytic macules of the
CC       lips, multiple gastrointestinal hamartomatous polyps and an
CC       increased risk for various neoplasms, including gastrointestinal
CC       cancer. {ECO:0000269|PubMed:10408777, ECO:0000269|PubMed:12372054,
CC       ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:21411391,
CC       ECO:0000269|PubMed:9425897, ECO:0000269|PubMed:9428765,
CC       ECO:0000269|PubMed:9760200, ECO:0000269|PubMed:9837816}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
CC       {ECO:0000269|PubMed:9605748, ECO:0000269|PubMed:9887330}. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Note=Defects in STK11 are associated with some sporadic
CC       cancers, especially lung cancers. Frequently mutated and
CC       inactivated in non-small cell lung cancer (NSCLC). Defects promote
CC       lung cancerigenesis process, especially lung cancer progression
CC       and metastasis. Confers lung adenocarcinoma the ability to trans-
CC       differentiate into squamous cell carcinoma. Also able to promotes
CC       lung cancer metastasis, via both cancer-cell autonomous and non-
CC       cancer-cell autonomous mechanisms.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. LKB1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STK11ID292.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=PJS entry;
CC       URL="https://en.wikipedia.org/wiki/PJS";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U63333; AAB05809.1; -; mRNA.
DR   EMBL; AF035625; AAC39527.1; -; mRNA.
DR   EMBL; AF032984; AAB97833.1; -; Genomic_DNA.
DR   EMBL; AF055327; AAC15742.1; -; Genomic_DNA.
DR   EMBL; AF055320; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055321; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055322; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055323; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055324; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055325; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AF055326; AAC15742.1; JOINED; Genomic_DNA.
DR   EMBL; AK314858; BAG37374.1; -; mRNA.
DR   EMBL; AC011544; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004221; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471139; EAW69540.1; -; Genomic_DNA.
DR   EMBL; BC007981; AAH07981.1; -; mRNA.
DR   EMBL; BC019334; AAH19334.1; -; mRNA.
DR   CCDS; CCDS45896.1; -. [Q15831-1]
DR   RefSeq; NP_000446.1; NM_000455.4. [Q15831-1]
DR   RefSeq; XP_005259675.1; XM_005259618.3. [Q15831-2]
DR   UniGene; Hs.515005; -.
DR   PDB; 2WTK; X-ray; 2.65 A; C/F=43-347.
DR   PDB; 4ZDR; X-ray; 2.90 A; A/B=333-340.
DR   PDBsum; 2WTK; -.
DR   PDBsum; 4ZDR; -.
DR   ProteinModelPortal; Q15831; -.
DR   SMR; Q15831; -.
DR   BioGrid; 112670; 91.
DR   DIP; DIP-31317N; -.
DR   IntAct; Q15831; 108.
DR   MINT; MINT-204048; -.
DR   STRING; 9606.ENSP00000324856; -.
DR   BindingDB; Q15831; -.
DR   ChEMBL; CHEMBL5606; -.
DR   GuidetoPHARMACOLOGY; 2212; -.
DR   iPTMnet; Q15831; -.
DR   PhosphoSitePlus; Q15831; -.
DR   BioMuta; STK11; -.
DR   DMDM; 3024670; -.
DR   EPD; Q15831; -.
DR   MaxQB; Q15831; -.
DR   PaxDb; Q15831; -.
DR   PeptideAtlas; Q15831; -.
DR   PRIDE; Q15831; -.
DR   DNASU; 6794; -.
DR   Ensembl; ENST00000326873; ENSP00000324856; ENSG00000118046. [Q15831-1]
DR   GeneID; 6794; -.
DR   KEGG; hsa:6794; -.
DR   UCSC; uc002lrl.2; human. [Q15831-1]
DR   CTD; 6794; -.
DR   DisGeNET; 6794; -.
DR   GeneCards; STK11; -.
DR   GeneReviews; STK11; -.
DR   HGNC; HGNC:11389; STK11.
DR   HPA; CAB016231; -.
DR   HPA; CAB022105; -.
DR   HPA; HPA017254; -.
DR   HPA; HPA067481; -.
DR   MalaCards; STK11; -.
DR   MIM; 175200; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 602216; gene.
DR   neXtProt; NX_Q15831; -.
DR   OpenTargets; ENSG00000118046; -.
DR   Orphanet; 2869; Peutz-Jeghers syndrome.
DR   PharmGKB; PA36198; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00530000063214; -.
DR   HOGENOM; HOG000007002; -.
DR   HOVERGEN; HBG054467; -.
DR   InParanoid; Q15831; -.
DR   KO; K07298; -.
DR   OMA; QQLGMFT; -.
DR   OrthoDB; EOG091G0BNP; -.
DR   PhylomeDB; Q15831; -.
DR   TreeFam; TF105322; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q15831; -.
DR   SIGNOR; Q15831; -.
DR   ChiTaRS; STK11; human.
DR   EvolutionaryTrace; Q15831; -.
DR   GeneWiki; STK11; -.
DR   GenomeRNAi; 6794; -.
DR   PRO; PR:Q15831; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000118046; -.
DR   CleanEx; HS_STK11; -.
DR   ExpressionAtlas; Q15831; baseline and differential.
DR   Genevisible; Q15831; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0036398; C:TCR signalosome; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0030275; F:LRR domain binding; IEA:Ensembl.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IDA:UniProtKB.
DR   GO; GO:0030295; F:protein kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:MGI.
DR   GO; GO:0043276; P:anoikis; IMP:BHF-UCL.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0071493; P:cellular response to UV-B; IDA:UniProtKB.
DR   GO; GO:0097484; P:dendrite extension; IEA:Ensembl.
DR   GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0051645; P:Golgi localization; IEA:Ensembl.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0060770; P:negative regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0051055; P:negative regulation of lipid biosynthetic process; IEA:Ensembl.
DR   GO; GO:1904262; P:negative regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0045059; P:positive thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0048814; P:regulation of dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0036399; P:TCR signalosome assembly; IEA:Ensembl.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   GO; GO:0001944; P:vasculature development; ISS:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_Ca-dep_prot_Kinase.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24347; PTHR24347; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Autophagy; Cell cycle; Complete proteome; Cytoplasm;
KW   Differentiation; Disease mutation; DNA damage; Kinase; Lipoprotein;
KW   Magnesium; Manganese; Membrane; Metal-binding; Methylation;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Palmitate; Phosphoprotein;
KW   Polymorphism; Prenylation; Reference proteome;
KW   Serine/threonine-protein kinase; Spermatogenesis; Transferase;
KW   Tumor suppressor.
FT   CHAIN         1    430       Serine/threonine-protein kinase STK11.
FT                                /FTId=PRO_0000086699.
FT   PROPEP      431    433       Removed in mature form. {ECO:0000250}.
FT                                /FTId=PRO_0000422300.
FT   DOMAIN       49    309       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      55     63       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       45     90       Sufficient for interaction with SIRT1.
FT                                {ECO:0000269|PubMed:18687677}.
FT   ACT_SITE    176    176       Proton acceptor.
FT   BINDING      78     78       ATP. {ECO:0000305}.
FT   MOD_RES      31     31       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      44     44       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES      48     48       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES      96     96       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES      97     97       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES     189    189       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11430832}.
FT   MOD_RES     296    296       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES     311    311       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES     325    325       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WTK7}.
FT   MOD_RES     336    336       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12805220}.
FT   MOD_RES     363    363       Phosphothreonine; by ATM and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:12805220}.
FT   MOD_RES     401    401       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     416    416       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES     423    423       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MOD_RES     428    428       Phosphoserine; by autocatalysis, PKA,
FT                                PKC/PRKCZ and RPS6KA1.
FT                                {ECO:0000269|PubMed:18321849,
FT                                ECO:0000269|PubMed:18854309}.
FT   MOD_RES     430    430       Cysteine methyl ester. {ECO:0000250}.
FT   MOD_RES     431    431       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:18687677}.
FT   LIPID       418    418       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID       430    430       S-farnesyl cysteine. {ECO:0000250}.
FT   VAR_SEQ     371    433       QVPEEEASHNGQRRGLPKAVCMNGTEAAQLSTKSRAEGRAP
FT                                NPARKACSASSKIRRLSACKQQ -> GEEASEAGLRAERGL
FT                                QKSEGSDLSGEEASRPAPQ (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_041746.
FT   VARIANT      14     14       E -> K (in cervical cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:12533684}.
FT                                /FTId=VAR_065627.
FT   VARIANT      16     16       E -> G (in PJS).
FT                                {ECO:0000269|PubMed:21411391}.
FT                                /FTId=VAR_065628.
FT   VARIANT      49     49       Y -> D (in melanoma; sporadic malignant;
FT                                somatic mutation; dbSNP:rs137853080).
FT                                {ECO:0000269|PubMed:10201537}.
FT                                /FTId=VAR_033138.
FT   VARIANT      50     53       Missing (in PJS).
FT                                {ECO:0000269|PubMed:9837816}.
FT                                /FTId=VAR_071057.
FT   VARIANT      66     66       V -> M (in cervical carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:12533684,
FT                                ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065629.
FT   VARIANT      67     67       L -> P (in PJS; abolishes kinase
FT                                activity, leading to loss of
FT                                autophosphorylation; dbSNP:rs137853077).
FT                                {ECO:0000269|PubMed:9428765,
FT                                ECO:0000269|PubMed:9837816}.
FT                                /FTId=VAR_006202.
FT   VARIANT      86     86       R -> G (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065630.
FT   VARIANT      87     87       R -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041139.
FT   VARIANT     123    123       Q -> R (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39;
FT                                dbSNP:rs764449808).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065631.
FT   VARIANT     135    135       G -> R (in melanoma; sporadic malignant;
FT                                somatic mutation; dbSNP:rs137853081).
FT                                {ECO:0000269|PubMed:10201537}.
FT                                /FTId=VAR_033139.
FT   VARIANT     157    157       F -> S (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065632.
FT   VARIANT     160    160       L -> P (in cervical cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:12533684}.
FT                                /FTId=VAR_065633.
FT   VARIANT     162    164       DGL -> NDM (in PJS).
FT                                /FTId=VAR_007920.
FT   VARIANT     163    163       G -> D (in TGCT; a tumor with seminoma
FT                                and teratoma components; associated with
FT                                severely impaired but detectable kinase
FT                                activity; somatic mutation; impairs
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39; predominantly nuclear
FT                                localization; dbSNP:rs137853078).
FT                                {ECO:0000269|PubMed:19892943,
FT                                ECO:0000269|PubMed:9605748,
FT                                ECO:0000269|PubMed:9887330}.
FT                                /FTId=VAR_033140.
FT   VARIANT     170    170       Q -> P (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065634.
FT   VARIANT     171    171       G -> S (in colorectal cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943,
FT                                ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065635.
FT   VARIANT     174    174       H -> R (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065636.
FT   VARIANT     176    176       D -> N (in PJS; loss of kinase activity,
FT                                leading to greatly reduced
FT                                autophosphorylation; fails to
FT                                phosphorylate PTEN in vitro; no
FT                                significant effect on nucleocytoplasmic
FT                                localization; dbSNP:rs730881979).
FT                                {ECO:0000269|PubMed:15987703,
FT                                ECO:0000269|PubMed:9837816}.
FT                                /FTId=VAR_071058.
FT   VARIANT     176    176       D -> Y (in sporadic cancer; somatic
FT                                mutation; Loss of kinase activity).
FT                                {ECO:0000269|PubMed:12805220,
FT                                ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065637.
FT   VARIANT     177    177       I -> N (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065638.
FT   VARIANT     181    181       N -> E (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39; requires
FT                                2 nucleotide substitutions).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065639.
FT   VARIANT     194    194       D -> N (in PJS; dbSNP:rs121913315).
FT                                {ECO:0000269|PubMed:10408777}.
FT                                /FTId=VAR_007921.
FT   VARIANT     194    194       D -> V (in lung cancer; somatic mutation;
FT                                dbSNP:rs121913316).
FT                                {ECO:0000269|PubMed:10079245}.
FT                                /FTId=VAR_065640.
FT   VARIANT     194    194       D -> Y (in melanoma; sporadic malignant;
FT                                somatic mutation; dbSNP:rs121913315).
FT                                {ECO:0000269|PubMed:10208439}.
FT                                /FTId=VAR_033141.
FT   VARIANT     199    199       E -> K (in colorectal cancer; somatic
FT                                mutation; impaired kinase activity;
FT                                dbSNP:rs121913317).
FT                                {ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065641.
FT   VARIANT     199    199       E -> Q (in sporadic cancer; somatic
FT                                mutation; does not affect kinase
FT                                activity). {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065642.
FT   VARIANT     205    205       A -> T (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39;
FT                                dbSNP:rs730881981).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065643.
FT   VARIANT     208    208       D -> N (in colorectal cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065644.
FT   VARIANT     215    215       G -> D (in colorectal cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065645.
FT   VARIANT     216    216       S -> F (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065646.
FT   VARIANT     223    223       E -> V (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065647.
FT   VARIANT     230    230       T -> P (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065648.
FT   VARIANT     231    231       F -> L (in cervical cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:12533684}.
FT                                /FTId=VAR_065649.
FT   VARIANT     232    232       S -> P (in sporadic cancer; somatic
FT                                mutation; no effect heterotrimeric
FT                                complex assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065650.
FT   VARIANT     239    239       W -> C (in PJS; late onset suggests
FT                                reduced penetrance; dbSNP:rs137853082).
FT                                {ECO:0000269|PubMed:12372054}.
FT                                /FTId=VAR_033142.
FT   VARIANT     245    245       L -> R (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065651.
FT   VARIANT     247    247       Missing (in PJS).
FT                                {ECO:0000269|PubMed:9760200}.
FT                                /FTId=VAR_006203.
FT   VARIANT     250    250       T -> P (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065652.
FT   VARIANT     272    272       Y -> H (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065653.
FT   VARIANT     277    277       D -> Y (in sporadic cancer; somatic
FT                                mutation; no effect on kinase activity
FT                                nor in heterotrimeric complex assembly
FT                                with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065654.
FT   VARIANT     281    281       P -> L (in ovarian carcinoma; somatic
FT                                mutation; dbSNP:rs121913322).
FT                                {ECO:0000269|PubMed:10429654}.
FT                                /FTId=VAR_065655.
FT   VARIANT     285    285       L -> Q (in sporadic cancer; somatic
FT                                mutation; impairs heterotrimeric complex
FT                                assembly with STRADA and CAB39).
FT                                {ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_065656.
FT   VARIANT     297    297       R -> K (in PJS).
FT                                {ECO:0000269|PubMed:10408777}.
FT                                /FTId=VAR_007922.
FT   VARIANT     303    306       IRQH -> N (in PJS).
FT                                /FTId=VAR_033143.
FT   VARIANT     308    308       W -> C (in PJS; abolishes kinase
FT                                activity, leading to loss of
FT                                autophosphorylation).
FT                                {ECO:0000269|PubMed:9837816}.
FT                                /FTId=VAR_071059.
FT   VARIANT     314    314       P -> H (in colorectal cancer; no effect
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39).
FT                                {ECO:0000269|PubMed:9809980}.
FT                                /FTId=VAR_065657.
FT   VARIANT     315    315       P -> S (in PJS; pathogenicity uncertain;
FT                                no effect heterotrimeric complex assembly
FT                                with STRADA and CAB39;
FT                                dbSNP:rs786202431).
FT                                {ECO:0000269|PubMed:12372054,
FT                                ECO:0000269|PubMed:19892943}.
FT                                /FTId=VAR_033144.
FT   VARIANT     324    324       P -> L (in gastric carcinoma; no effect
FT                                heterotrimeric complex assembly with
FT                                STRADA and CAB39; dbSNP:rs367807476).
FT                                {ECO:0000269|PubMed:9683800}.
FT                                /FTId=VAR_065658.
FT   VARIANT     354    354       F -> L (in colorectal cancer; somatic
FT                                mutation; dbSNP:rs59912467).
FT                                {ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065659.
FT   VARIANT     367    367       T -> M (in colorectal cancer; somatic
FT                                mutation; dbSNP:rs587782835).
FT                                {ECO:0000269|PubMed:9731485}.
FT                                /FTId=VAR_065660.
FT   MUTAGEN      44     44       K->R: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MUTAGEN      48     48       K->Q: No effect on basal
FT                                nucleocytoplasmic localization, but fails
FT                                to translocate to the cytoplasm when
FT                                coexpressed with SIRT1.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MUTAGEN      48     48       K->R: Enhanced phosphorylation at Thr-336
FT                                and Ser-428, enhanced cytoplasmic
FT                                localization and increased kinase
FT                                activity. {ECO:0000269|PubMed:18687677}.
FT   MUTAGEN      74     74       R->A: Impaired formation of a
FT                                heterotrimeric complex with STRADA and
FT                                CAB39; when associated with A-204.
FT                                {ECO:0000269|PubMed:19892943}.
FT   MUTAGEN      78     78       K->I: Loss of kinase activity, leading to
FT                                greatly reduced autophosphorylation.
FT                                {ECO:0000269|PubMed:11430832,
FT                                ECO:0000269|PubMed:9837816}.
FT   MUTAGEN      78     78       K->M: Loss of kinase activity, leading to
FT                                reduced autophosphorylation and acting as
FT                                a dominant-negative mutant.
FT                                {ECO:0000269|PubMed:11430832,
FT                                ECO:0000269|PubMed:9837816}.
FT   MUTAGEN      96     96       K->R: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MUTAGEN      97     97       K->R: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:18687677}.
FT   MUTAGEN     189    189       T->A: Reduced phosphorylation.
FT                                {ECO:0000269|PubMed:11430832}.
FT   MUTAGEN     194    194       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:14517248,
FT                                ECO:0000269|PubMed:14976552,
FT                                ECO:0000269|PubMed:19892943}.
FT   MUTAGEN     204    204       F->A: No effect. Impaired formation of a
FT                                heterotrimeric complex with STRADA and
FT                                CAB39; when associated with A-74.
FT                                {ECO:0000269|PubMed:19892943}.
FT   MUTAGEN     428    428       S->A,E: No effect on kinase activity.
FT                                {ECO:0000269|PubMed:18321849,
FT                                ECO:0000269|PubMed:18854309}.
FT   MUTAGEN     428    428       S->A: Inhibits peroxynitrite-induced
FT                                nuclear export of STK11, and consequent
FT                                PTEN phosphorylation and inhibition of
FT                                PI3K/Akt signaling.
FT                                {ECO:0000269|PubMed:18321849,
FT                                ECO:0000269|PubMed:18854309}.
FT   STRAND       54     57       {ECO:0000244|PDB:2WTK}.
FT   STRAND       62     68       {ECO:0000244|PDB:2WTK}.
FT   TURN         69     71       {ECO:0000244|PDB:2WTK}.
FT   STRAND       74     80       {ECO:0000244|PDB:2WTK}.
FT   HELIX        82     87       {ECO:0000244|PDB:2WTK}.
FT   HELIX        91    102       {ECO:0000244|PDB:2WTK}.
FT   STRAND      113    118       {ECO:0000244|PDB:2WTK}.
FT   STRAND      125    130       {ECO:0000244|PDB:2WTK}.
FT   STRAND      133    135       {ECO:0000244|PDB:2WTK}.
FT   HELIX       136    142       {ECO:0000244|PDB:2WTK}.
FT   HELIX       150    169       {ECO:0000244|PDB:2WTK}.
FT   HELIX       179    181       {ECO:0000244|PDB:2WTK}.
FT   STRAND      182    184       {ECO:0000244|PDB:2WTK}.
FT   STRAND      190    192       {ECO:0000244|PDB:2WTK}.
FT   HELIX       217    219       {ECO:0000244|PDB:2WTK}.
FT   HELIX       222    225       {ECO:0000244|PDB:2WTK}.
FT   STRAND      231    233       {ECO:0000244|PDB:2WTK}.
FT   HELIX       234    250       {ECO:0000244|PDB:2WTK}.
FT   HELIX       260    269       {ECO:0000244|PDB:2WTK}.
FT   STRAND      276    278       {ECO:0000244|PDB:2WTK}.
FT   HELIX       280    289       {ECO:0000244|PDB:2WTK}.
FT   TURN        294    296       {ECO:0000244|PDB:2WTK}.
FT   HELIX       300    305       {ECO:0000244|PDB:2WTK}.
FT   HELIX       307    310       {ECO:0000244|PDB:2WTK}.
FT   HELIX       334    336       {ECO:0000244|PDB:4ZDR}.
FT   HELIX       339    341       {ECO:0000244|PDB:2WTK}.
SQ   SEQUENCE   433 AA;  48636 MW;  6DF4C37AB7A89569 CRC64;
     MEVVDPQQLG MFTEGELMSV GMDTFIHRID STEVIYQPRR KRAKLIGKYL MGDLLGEGSY
     GKVKEVLDSE TLCRRAVKIL KKKKLRRIPN GEANVKKEIQ LLRRLRHKNV IQLVDVLYNE
     EKQKMYMVME YCVCGMQEML DSVPEKRFPV CQAHGYFCQL IDGLEYLHSQ GIVHKDIKPG
     NLLLTTGGTL KISDLGVAEA LHPFAADDTC RTSQGSPAFQ PPEIANGLDT FSGFKVDIWS
     AGVTLYNITT GLYPFEGDNI YKLFENIGKG SYAIPGDCGP PLSDLLKGML EYEPAKRFSI
     RQIRQHSWFR KKHPPAEAPV PIPPSPDTKD RWRSMTVVPY LEDLHGADED EDLFDIEDDI
     IYTQDFTVPG QVPEEEASHN GQRRGLPKAV CMNGTEAAQL STKSRAEGRA PNPARKACSA
     SSKIRRLSAC KQQ
//
